Engineering Telodendrimer Nanocarriers for Monomeric Amphotericin B Delivery
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.2c01087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Xiaotian Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, New York 13210, United States. Hauptthemen laut MEDLINE: Amphotericin B, Mycoses. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Heart, Lung, and Blood Institute, Ovarian Cancer Research Foundation, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Systemic fungal infections are an increasingly prevalent health problem. Amphotericin B (AmB), a hydrophobic polyene antibiotic, remains the drug of choice for life-threatening invasive fungal infections. However, it has dose-limiting side effects, including nephrotoxicity. The efficacy and toxicity of AmB are directly related to its aggregation state. Here, we report the preparation of a series of telodendrimer (TD) nanocarriers with the freely engineered core structures for AmB encapsulation to fine-tune AmB aggregation status. The reduced aggregation status correlates well with the optimized antifungal activity, attenuated hemolytic properties, and reduced cytotoxicity to mammalian cells. The optimized TD nanocarrier for monomeric AmB encapsulation significantly increases the therapeutic index, reduces the in vivo toxicity, and enhances antifungal effects in mouse models with Candida albicans infection in comparison to two common clinical formulations, i.e., Fungizone and AmBisome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
- Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
- Department of Pharmacology, Department of Surgery, Department of Microbiology and Immunology, Upstate Cancer Center, Upstate Sepsis Interdisciplinary Research Center, State University of New York Upstate Medical Univers…
ORCID-Profile: Juntao Luo
Förderung
- National Heart, Lung, and Blood Institute
- Ovarian Cancer Research Foundation
- National Institute of General Medical Sciences
- New York Fund for Innovation in Research and Scientific Talent
Zitieren
APA
Ji, X., Shi, C., Guo, D., Yang, X., Suo, L., & Luo, J. (2023). Engineering Telodendrimer Nanocarriers for Monomeric Amphotericin B Delivery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c01087
Vancouver
Ji X, Shi C, Guo D, Yang X, Suo L, Luo J. Engineering Telodendrimer Nanocarriers for Monomeric Amphotericin B Delivery. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c01087
BibTeX
@article{Ji2023,
author = {Ji, Xiaotian and Shi, Changying and Guo, Dandan and Yang, Xiguang and Suo, Liye and Luo, Juntao},
title = {Engineering Telodendrimer Nanocarriers for Monomeric Amphotericin B Delivery},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.2c01087}
}
EUVIMED